What we do Cohance Lifesciences Limited is a global integrated Contract Development and Manufacturing Operations (CDMO) company specializing in custom synthesis, process R&D, and manufacturing of pharmaceutical intermediates, APIs, and formulations. |
Founded in 2,018 |
Market share Strong global presence serving top 20 innovators; expanding niche modalities and high-growth segments like ADCs and oligonucleotides. |
Problem solved Supports global pharma and biotech clients in accelerating new chemical entity development and complex molecule manufacturing with advanced capabilities. |
Top clients or who we serve Serves global pharmaceutical, biotechnology, agrochemical, and specialty chemical companies, primarily B2B with prominent innovator clientele. |
Key management Mr. Vivek Sharma (Executive Chairman), Dr. V Prasada Raju (Managing Director), Dr. Sudhir Kumar Singh (CEO). |
Our journey and innovations Founded in 2018; acquired Sapala Organics and NJ Bio focusing on oligonucleotides and ADCs; merged Casper Pharma; evolving toward science-led CDMO with novel modality platforms. |
Where we operate Operations and clients span USA, Europe, India, and Asia-Pacific with growing footprint in high-value niche modalities globally. |
Top products or what we offer Custom synthesis and manufacturing of intermediates, APIs, specialty chemicals, oligonucleotides, antibody-drug conjugates, controlled substances, and formulations. |
Top brands Pharma CDMO services, Sapala (Oligos and nucleic acid building blocks), NJ Bio (ADC and bioconjugation services), Casper Pharma (formulations and pharma intermediates). |
Raw materials needed Chemical precursors, active pharmaceutical ingredients, specialty reagents, oligonucleotide building blocks, payloads and linkers for ADCs. |
Raw materials supplier Global chemical suppliers and intermediates providers; specifics confidential due to proprietary processes. |
Recurring vs cyclical contribution Revenue is a mix of recurring long-term contracts and cyclical project-based business tied to drug development stages. |
Our industry position Among top contract pharmaceutical manufacturers globally; recognized for expertise in complex chemistries and emerging modalities. |
Financial highlights FY24-25 revenue ₹1,198 Cr with consolidated profit after tax ₹265 Cr; robust EBITDA margins ~37%; growing with strategic acquisitions and organic expansion. |
Geographical revenue split Europe leads with ₹759 Cr, USA ₹255 Cr, India ₹75 Cr, and others ₹84 Cr contributing to total revenue. |
Order book Strong and diverse pipeline with >100 active projects across discovery to commercial stages, including 9 molecules in Phase III clinical trials. |
Whats driving growth Growth driven by modality expansion in ADCs and oligonucleotides, strategic acquisitions, increased innovator collaborations, and supply chain diversification. |
Our future plans Capex focused on expanding high-containment, oligonucleotide GMP facilities, and ADC platform; merging acquired entities for efficiency; ESG advancement. |
Our green promise Committed to sustainability with EcoVadis Gold rating, targets for renewable energy use, emission reductions, and strict environmental standards. |
Our people and values Team strengthened with PhD scientists and industry veterans fostering customer-centric, performance-driven culture emphasizing innovation and diversity. |
Key challenges ahead Near-term growth affected by pharma destocking, plant shut-down for regulatory upgrades, and biotech funding slowdowns affecting project timelines. |
Interesting facts Only global supplier of Tricyclo-DNA Amidites; leader in topoisomerase-I payloads; 22 successful US FDA audits; expanding cutting-edge ADC and oligo modalities. |
Risks and strategy Risks from regulatory delays, market cycles, and competition mitigated by R&D investments, strategic partnerships, and operational excellence. |
